BELLUS Health Inc (BLU)

[I-Man]

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today announced that three abstracts on BLU-5937 have been accepted for presentation at the upcoming American Thoracic Society ("ATS") 2021 International Conference, being held on May 14-19, 2021.

Mini Symposium Presentation:

Title: Improvements in Cough Frequency Over 24 Hours with BLU-5937, a Selective P2X3 Antagonist, in Patient Subgroups Defined by Baseline Awake Cough Frequencies Session: Hot Takes from Clinical Trials in Lung Disease (A006) Format: Pre-recorded presentation and live discussion period Date: Sunday, May 16 Time: 10:00 - 11:30 a.m. EDT

Poster Presentations:

Title: Design of SOOTHE, a Phase 2b Dose Finding Study with BLU-5937, a Selective P2X3 Antagonist, in Refractory Chronic Cough Session: Assessment and Treatment of Cough and Chronic Dyspnea (TP044) Format: On demand

Title: Baseline Characteristics and Burden of Disease in Populations Defined by Cough Frequency Tiers in RELIEF, a Phase 2 Study on the Efficacy and Safety of BLU-5937 in Refractory Chronic Cough Session: Assessment and Treatment of Cough and Chronic Dyspnea (TP044) Format: On demand

Following the conference, the presentation materials will be available in the "Scientific Publications" section of BELLUS Health's website at www.bellushealth.com.